Karyopharm Therapeutics Inc. (KPTI) Lowered to Sell at ValuEngine
ValuEngine cut shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from a hold rating to a sell rating in a report released on Thursday morning.
Other equities research analysts have also recently issued reports about the company. Canaccord Genuity set a $18.00 target price on Karyopharm Therapeutics and gave the stock a buy rating in a research note on Tuesday, August 8th. Jefferies Group LLC reiterated a buy rating and set a $19.00 target price (up from $16.00) on shares of Karyopharm Therapeutics in a research note on Thursday, August 10th. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the stock a buy rating in a research note on Saturday, June 24th. Zacks Investment Research upgraded Karyopharm Therapeutics from a hold rating to a buy rating and set a $11.00 target price on the stock in a research note on Thursday, July 6th. Finally, BidaskClub upgraded Karyopharm Therapeutics from a sell rating to a hold rating in a research note on Friday, August 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $15.33.
Karyopharm Therapeutics (NASDAQ KPTI) traded down 1.76% during trading on Thursday, hitting $10.04. 41,480 shares of the company’s stock traded hands. The company’s market cap is $473.27 million. Karyopharm Therapeutics has a 52-week low of $6.27 and a 52-week high of $14.63. The company’s 50 day moving average price is $8.93 and its 200 day moving average price is $9.86.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The firm’s revenue for the quarter was down 95.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.84) EPS. Analysts expect that Karyopharm Therapeutics will post ($2.68) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Karyopharm Therapeutics Inc. (KPTI) Lowered to Sell at ValuEngine” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/01/karyopharm-therapeutics-inc-kpti-lowered-to-sell-at-valuengine.html.
Large investors have recently made changes to their positions in the company. Teza Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics during the first quarter valued at $169,000. Voya Investment Management LLC raised its stake in shares of Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after buying an additional 4,444 shares during the period. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics during the second quarter valued at $136,000. American International Group Inc. raised its stake in shares of Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after buying an additional 2,836 shares during the period. Finally, Trexquant Investment LP purchased a new stake in shares of Karyopharm Therapeutics during the second quarter valued at $202,000. 58.97% of the stock is owned by institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.